English
简体中文
Total: £ 56.28
Published Date: 2025-10-17 | Pages: 156 | Tables: 159 | Medical Care
The global mRNA Vaccine Raw Materials market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
The development and production of mRNA vaccines is relatively simple, scalable, and extremely rapid. mRNA is produced in vitro through an enzymatic process without the need to remove cells or host cell proteins. This simplified production process allows GMP facilities to be converted to produce new protein targets in a very short period of time, with only minimal changes to the process and formulation.
From a downstream perspective, (non-replicating) mRNA vaccine accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
mRNA Vaccine Raw Materials leading manufacturers including Thermo Fisher Scientific Inc., Danaher Corporation, Kaneka Eurogentec S.A., BioSpring, GenScript, Aji Bio-Pharma, Merck KGaA, Aldevron, Hongene, WuXi Biologics, etc., dominate supply; the top five capture approximately % of global revenue, with Thermo Fisher Scientific Inc. leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global mRNA Vaccine Raw Materials market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Thermo Fisher Scientific Inc.
Danaher Corporation
Kaneka Eurogentec S.A.
BioSpring
GenScript
Aji Bio-Pharma
Merck KGaA
Aldevron
Hongene
WuXi Biologics
Asymchem
Cosychem
Novoprotein
Vazyme
Yeasen
KACTUS
Segment by Type
Plasmid DNA (pDNA)
Enzyme
Other
Segment by Application
(non-replicating) mRNA vaccine
(self-amplifying) mRNA vaccine
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the mRNA Vaccine Raw Materials study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to mRNA Vaccine Raw Materials: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global mRNA Vaccine Raw Materials Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Plasmid DNA (pDNA)
1.2.3 Enzyme
1.2.4 Other
1.3 Market Segmentation by Application
1.3.1 Global mRNA Vaccine Raw Materials Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 (non-replicating) mRNA vaccine
1.3.3 (self-amplifying) mRNA vaccine
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global mRNA Vaccine Raw Materials Revenue Estimates and Forecasts 2020-2031
2.2 Global mRNA Vaccine Raw Materials Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global mRNA Vaccine Raw Materials Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global mRNA Vaccine Raw Materials Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Plasmid DNA (pDNA) Market Size by Players
3.3.2 Enzyme Market Size by Players
3.3.3 Other Market Size by Players
3.4 Global mRNA Vaccine Raw Materials Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global mRNA Vaccine Raw Materials Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global mRNA Vaccine Raw Materials Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America mRNA Vaccine Raw Materials Market Size by Type (2020-2031)
6.4 North America mRNA Vaccine Raw Materials Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America mRNA Vaccine Raw Materials Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe mRNA Vaccine Raw Materials Market Size by Type (2020-2031)
7.4 Europe mRNA Vaccine Raw Materials Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe mRNA Vaccine Raw Materials Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific mRNA Vaccine Raw Materials Market Size by Type (2020-2031)
8.4 Asia-Pacific mRNA Vaccine Raw Materials Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific mRNA Vaccine Raw Materials Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America mRNA Vaccine Raw Materials Market Size by Type (2020-2031)
9.4 Central and South America mRNA Vaccine Raw Materials Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America mRNA Vaccine Raw Materials Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa mRNA Vaccine Raw Materials Market Size by Type (2020-2031)
10.4 Middle East and Africa mRNA Vaccine Raw Materials Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa mRNA Vaccine Raw Materials Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Thermo Fisher Scientific Inc.
11.1.1 Thermo Fisher Scientific Inc. Corporation Information
11.1.2 Thermo Fisher Scientific Inc. Business Overview
11.1.3 Thermo Fisher Scientific Inc. mRNA Vaccine Raw Materials Product Features and Attributes
11.1.4 Thermo Fisher Scientific Inc. mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.1.5 Thermo Fisher Scientific Inc. mRNA Vaccine Raw Materials Revenue by Product in 2024
11.1.6 Thermo Fisher Scientific Inc. mRNA Vaccine Raw Materials Revenue by Application in 2024
11.1.7 Thermo Fisher Scientific Inc. mRNA Vaccine Raw Materials Revenue by Geographic Area in 2024
11.1.8 Thermo Fisher Scientific Inc. mRNA Vaccine Raw Materials SWOT Analysis
11.1.9 Thermo Fisher Scientific Inc. Recent Developments
11.2 Danaher Corporation
11.2.1 Danaher Corporation Corporation Information
11.2.2 Danaher Corporation Business Overview
11.2.3 Danaher Corporation mRNA Vaccine Raw Materials Product Features and Attributes
11.2.4 Danaher Corporation mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.2.5 Danaher Corporation mRNA Vaccine Raw Materials Revenue by Product in 2024
11.2.6 Danaher Corporation mRNA Vaccine Raw Materials Revenue by Application in 2024
11.2.7 Danaher Corporation mRNA Vaccine Raw Materials Revenue by Geographic Area in 2024
11.2.8 Danaher Corporation mRNA Vaccine Raw Materials SWOT Analysis
11.2.9 Danaher Corporation Recent Developments
11.3 Kaneka Eurogentec S.A.
11.3.1 Kaneka Eurogentec S.A. Corporation Information
11.3.2 Kaneka Eurogentec S.A. Business Overview
11.3.3 Kaneka Eurogentec S.A. mRNA Vaccine Raw Materials Product Features and Attributes
11.3.4 Kaneka Eurogentec S.A. mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.3.5 Kaneka Eurogentec S.A. mRNA Vaccine Raw Materials Revenue by Product in 2024
11.3.6 Kaneka Eurogentec S.A. mRNA Vaccine Raw Materials Revenue by Application in 2024
11.3.7 Kaneka Eurogentec S.A. mRNA Vaccine Raw Materials Revenue by Geographic Area in 2024
11.3.8 Kaneka Eurogentec S.A. mRNA Vaccine Raw Materials SWOT Analysis
11.3.9 Kaneka Eurogentec S.A. Recent Developments
11.4 BioSpring
11.4.1 BioSpring Corporation Information
11.4.2 BioSpring Business Overview
11.4.3 BioSpring mRNA Vaccine Raw Materials Product Features and Attributes
11.4.4 BioSpring mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.4.5 BioSpring mRNA Vaccine Raw Materials Revenue by Product in 2024
11.4.6 BioSpring mRNA Vaccine Raw Materials Revenue by Application in 2024
11.4.7 BioSpring mRNA Vaccine Raw Materials Revenue by Geographic Area in 2024
11.4.8 BioSpring mRNA Vaccine Raw Materials SWOT Analysis
11.4.9 BioSpring Recent Developments
11.5 GenScript
11.5.1 GenScript Corporation Information
11.5.2 GenScript Business Overview
11.5.3 GenScript mRNA Vaccine Raw Materials Product Features and Attributes
11.5.4 GenScript mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.5.5 GenScript mRNA Vaccine Raw Materials Revenue by Product in 2024
11.5.6 GenScript mRNA Vaccine Raw Materials Revenue by Application in 2024
11.5.7 GenScript mRNA Vaccine Raw Materials Revenue by Geographic Area in 2024
11.5.8 GenScript mRNA Vaccine Raw Materials SWOT Analysis
11.5.9 GenScript Recent Developments
11.6 Aji Bio-Pharma
11.6.1 Aji Bio-Pharma Corporation Information
11.6.2 Aji Bio-Pharma Business Overview
11.6.3 Aji Bio-Pharma mRNA Vaccine Raw Materials Product Features and Attributes
11.6.4 Aji Bio-Pharma mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.6.5 Aji Bio-Pharma Recent Developments
11.7 Merck KGaA
11.7.1 Merck KGaA Corporation Information
11.7.2 Merck KGaA Business Overview
11.7.3 Merck KGaA mRNA Vaccine Raw Materials Product Features and Attributes
11.7.4 Merck KGaA mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.7.5 Merck KGaA Recent Developments
11.8 Aldevron
11.8.1 Aldevron Corporation Information
11.8.2 Aldevron Business Overview
11.8.3 Aldevron mRNA Vaccine Raw Materials Product Features and Attributes
11.8.4 Aldevron mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.8.5 Aldevron Recent Developments
11.9 Hongene
11.9.1 Hongene Corporation Information
11.9.2 Hongene Business Overview
11.9.3 Hongene mRNA Vaccine Raw Materials Product Features and Attributes
11.9.4 Hongene mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.9.5 Hongene Recent Developments
11.10 WuXi Biologics
11.10.1 WuXi Biologics Corporation Information
11.10.2 WuXi Biologics Business Overview
11.10.3 WuXi Biologics mRNA Vaccine Raw Materials Product Features and Attributes
11.10.4 WuXi Biologics mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Asymchem
11.11.1 Asymchem Corporation Information
11.11.2 Asymchem Business Overview
11.11.3 Asymchem mRNA Vaccine Raw Materials Product Features and Attributes
11.11.4 Asymchem mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.11.5 Asymchem Recent Developments
11.12 Cosychem
11.12.1 Cosychem Corporation Information
11.12.2 Cosychem Business Overview
11.12.3 Cosychem mRNA Vaccine Raw Materials Product Features and Attributes
11.12.4 Cosychem mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.12.5 Cosychem Recent Developments
11.13 Novoprotein
11.13.1 Novoprotein Corporation Information
11.13.2 Novoprotein Business Overview
11.13.3 Novoprotein mRNA Vaccine Raw Materials Product Features and Attributes
11.13.4 Novoprotein mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.13.5 Novoprotein Recent Developments
11.14 Vazyme
11.14.1 Vazyme Corporation Information
11.14.2 Vazyme Business Overview
11.14.3 Vazyme mRNA Vaccine Raw Materials Product Features and Attributes
11.14.4 Vazyme mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.14.5 Vazyme Recent Developments
11.15 Yeasen
11.15.1 Yeasen Corporation Information
11.15.2 Yeasen Business Overview
11.15.3 Yeasen mRNA Vaccine Raw Materials Product Features and Attributes
11.15.4 Yeasen mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.15.5 Yeasen Recent Developments
11.16 KACTUS
11.16.1 KACTUS Corporation Information
11.16.2 KACTUS Business Overview
11.16.3 KACTUS mRNA Vaccine Raw Materials Product Features and Attributes
11.16.4 KACTUS mRNA Vaccine Raw Materials Revenue and Gross Margin (2020-2025)
11.16.5 KACTUS Recent Developments
12 mRNA Vaccine Raw MaterialsIndustry Chain Analysis
12.1 mRNA Vaccine Raw Materials Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 mRNA Vaccine Raw Materials Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global mRNA Vaccine Raw Materials Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global mRNA Vaccine Raw Materials Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global mRNA Vaccine Raw Materials Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global mRNA Vaccine Raw Materials Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global mRNA Vaccine Raw Materials Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global mRNA Vaccine Raw Materials Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global mRNA Vaccine Raw Materials Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global mRNA Vaccine Raw Materials Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global mRNA Vaccine Raw Materials by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Vaccine Raw Materials as of 2024)
Table 11. Global mRNA Vaccine Raw Materials Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global mRNA Vaccine Raw Materials Companies Headquarters
Table 13. Global mRNA Vaccine Raw Materials Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global mRNA Vaccine Raw Materials Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global mRNA Vaccine Raw Materials Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global mRNA Vaccine Raw Materials Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global mRNA Vaccine Raw Materials Revenue by Application (2026-2031) & (US$ Million)
Table 21. mRNA Vaccine Raw Materials High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America mRNA Vaccine Raw Materials Growth Accelerators and Market Barriers
Table 25. North America mRNA Vaccine Raw Materials Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe mRNA Vaccine Raw Materials Growth Accelerators and Market Barriers
Table 27. Europe mRNA Vaccine Raw Materials Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific mRNA Vaccine Raw Materials Growth Accelerators and Market Barriers
Table 29. Asia-Pacific mRNA Vaccine Raw Materials Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America mRNA Vaccine Raw Materials Investment Opportunities and Key Challenges
Table 31. Central and South America mRNA Vaccine Raw Materials Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa mRNA Vaccine Raw Materials Investment Opportunities and Key Challenges
Table 33. Middle East and Africa mRNA Vaccine Raw Materials Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Thermo Fisher Scientific Inc. Corporation Information
Table 35. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 36. Thermo Fisher Scientific Inc. Product Features and Attributes
Table 37. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Thermo Fisher Scientific Inc. Revenue Proportion by Product in 2024
Table 39. Thermo Fisher Scientific Inc. Revenue Proportion by Application in 2024
Table 40. Thermo Fisher Scientific Inc. Revenue Proportion by Geographic Area in 2024
Table 41. Thermo Fisher Scientific Inc. mRNA Vaccine Raw Materials SWOT Analysis
Table 42. Thermo Fisher Scientific Inc. Recent Developments
Table 43. Danaher Corporation Corporation Information
Table 44. Danaher Corporation Description and Major Businesses
Table 45. Danaher Corporation Product Features and Attributes
Table 46. Danaher Corporation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Danaher Corporation Revenue Proportion by Product in 2024
Table 48. Danaher Corporation Revenue Proportion by Application in 2024
Table 49. Danaher Corporation Revenue Proportion by Geographic Area in 2024
Table 50. Danaher Corporation mRNA Vaccine Raw Materials SWOT Analysis
Table 51. Danaher Corporation Recent Developments
Table 52. Kaneka Eurogentec S.A. Corporation Information
Table 53. Kaneka Eurogentec S.A. Description and Major Businesses
Table 54. Kaneka Eurogentec S.A. Product Features and Attributes
Table 55. Kaneka Eurogentec S.A. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Kaneka Eurogentec S.A. Revenue Proportion by Product in 2024
Table 57. Kaneka Eurogentec S.A. Revenue Proportion by Application in 2024
Table 58. Kaneka Eurogentec S.A. Revenue Proportion by Geographic Area in 2024
Table 59. Kaneka Eurogentec S.A. mRNA Vaccine Raw Materials SWOT Analysis
Table 60. Kaneka Eurogentec S.A. Recent Developments
Table 61. BioSpring Corporation Information
Table 62. BioSpring Description and Major Businesses
Table 63. BioSpring Product Features and Attributes
Table 64. BioSpring Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. BioSpring Revenue Proportion by Product in 2024
Table 66. BioSpring Revenue Proportion by Application in 2024
Table 67. BioSpring Revenue Proportion by Geographic Area in 2024
Table 68. BioSpring mRNA Vaccine Raw Materials SWOT Analysis
Table 69. BioSpring Recent Developments
Table 70. GenScript Corporation Information
Table 71. GenScript Description and Major Businesses
Table 72. GenScript Product Features and Attributes
Table 73. GenScript Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. GenScript Revenue Proportion by Product in 2024
Table 75. GenScript Revenue Proportion by Application in 2024
Table 76. GenScript Revenue Proportion by Geographic Area in 2024
Table 77. GenScript mRNA Vaccine Raw Materials SWOT Analysis
Table 78. GenScript Recent Developments
Table 79. Aji Bio-Pharma Corporation Information
Table 80. Aji Bio-Pharma Description and Major Businesses
Table 81. Aji Bio-Pharma Product Features and Attributes
Table 82. Aji Bio-Pharma Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Aji Bio-Pharma Recent Developments
Table 84. Merck KGaA Corporation Information
Table 85. Merck KGaA Description and Major Businesses
Table 86. Merck KGaA Product Features and Attributes
Table 87. Merck KGaA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Merck KGaA Recent Developments
Table 89. Aldevron Corporation Information
Table 90. Aldevron Description and Major Businesses
Table 91. Aldevron Product Features and Attributes
Table 92. Aldevron Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Aldevron Recent Developments
Table 94. Hongene Corporation Information
Table 95. Hongene Description and Major Businesses
Table 96. Hongene Product Features and Attributes
Table 97. Hongene Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Hongene Recent Developments
Table 99. WuXi Biologics Corporation Information
Table 100. WuXi Biologics Description and Major Businesses
Table 101. WuXi Biologics Product Features and Attributes
Table 102. WuXi Biologics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. WuXi Biologics Recent Developments
Table 104. Asymchem Corporation Information
Table 105. Asymchem Description and Major Businesses
Table 106. Asymchem Product Features and Attributes
Table 107. Asymchem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Asymchem Recent Developments
Table 109. Cosychem Corporation Information
Table 110. Cosychem Description and Major Businesses
Table 111. Cosychem Product Features and Attributes
Table 112. Cosychem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Cosychem Recent Developments
Table 114. Novoprotein Corporation Information
Table 115. Novoprotein Description and Major Businesses
Table 116. Novoprotein Product Features and Attributes
Table 117. Novoprotein Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Novoprotein Recent Developments
Table 119. Vazyme Corporation Information
Table 120. Vazyme Description and Major Businesses
Table 121. Vazyme Product Features and Attributes
Table 122. Vazyme Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Vazyme Recent Developments
Table 124. Yeasen Corporation Information
Table 125. Yeasen Description and Major Businesses
Table 126. Yeasen Product Features and Attributes
Table 127. Yeasen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Yeasen Recent Developments
Table 129. KACTUS Corporation Information
Table 130. KACTUS Description and Major Businesses
Table 131. KACTUS Product Features and Attributes
Table 132. KACTUS Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. KACTUS Recent Developments
Table 134. Raw Materials Key Suppliers
Table 135. Distributors List
Table 136. Market Trends and Market Evolution
Table 137. Market Drivers and Opportunities
Table 138. Market Challenges, Risks, and Restraints
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. mRNA Vaccine Raw Materials Product Picture
Figure 2. Global mRNA Vaccine Raw Materials Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Plasmid DNA (pDNA) Product Picture
Figure 4. Enzyme Product Picture
Figure 5. Other Product Picture
Figure 6. Global mRNA Vaccine Raw Materials Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. (non-replicating) mRNA vaccine
Figure 8. (self-amplifying) mRNA vaccine
Figure 9. mRNA Vaccine Raw Materials Report Years Considered
Figure 10. Global mRNA Vaccine Raw Materials Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 12. Global mRNA Vaccine Raw Materials Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global mRNA Vaccine Raw Materials Revenue Market Share by Region (2020-2031)
Figure 14. Global mRNA Vaccine Raw Materials Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. Plasmid DNA (pDNA) Revenue Market Share by Player in 2024
Figure 17. Enzyme Revenue Market Share by Player in 2024
Figure 18. Other Revenue Market Share by Player in 2024
Figure 19. Global mRNA Vaccine Raw Materials Revenue Market Share by Type (2020-2031)
Figure 20. Global mRNA Vaccine Raw Materials Revenue Market Share by Application (2020-2031)
Figure 21. North America mRNA Vaccine Raw Materials Revenue YoY (2020-2031) & (US$ Million)
Figure 22. North America Top 5 Players mRNA Vaccine Raw Materials Revenue (US$ Million) in 2024
Figure 23. North America mRNA Vaccine Raw Materials Revenue (US$ Million) by Type (2020 - 2031)
Figure 24. North America mRNA Vaccine Raw Materials Revenue (US$ Million) by Application (2020-2031)
Figure 25. US mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 26. Canada mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 27. Mexico mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 28. Europe mRNA Vaccine Raw Materials Revenue YoY (2020-2031) & (US$ Million)
Figure 29. Europe Top 5 Players mRNA Vaccine Raw Materials Revenue (US$ Million) in 2024
Figure 30. Europe mRNA Vaccine Raw Materials Revenue (US$ Million) by Type (2020-2031)
Figure 31. Europe mRNA Vaccine Raw Materials Revenue (US$ Million) by Application (2020-2031)
Figure 32. Germany mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 33. France mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 34. U.K. mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 35. Italy mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 36. Russia mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific mRNA Vaccine Raw Materials Revenue YoY (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Top 8 Players mRNA Vaccine Raw Materials Revenue (US$ Million) in 2024
Figure 39. Asia-Pacific mRNA Vaccine Raw Materials Revenue (US$ Million) by Type (2020-2031)
Figure 40. Asia-Pacific mRNA Vaccine Raw Materials Revenue (US$ Million) by Application (2020-2031)
Figure 41. Indonesia mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 42. Japan mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 43. South Korea mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 44. Australia mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 45. India mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 46. Indonesia mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 47. Vietnam mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 48. Malaysia mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 49. Philippines mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 50. Singapore mRNA Vaccine Raw Materials Revenue (2020-2031) & (US$ Million)
Figure 51. Central and South America mRNA Vaccine Raw Materials Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Central and South America Top 5 Players mRNA Vaccine Raw Materials Revenue (US$ Million) in 2024
Figure 53. Central and South America mRNA Vaccine Raw Materials Revenue (US$ Million) by Type (2020-2031)
Figure 54. Central and South America mRNA Vaccine Raw Materials Revenue (US$ Million) by Application (2020-2031)
Figure 55. Brazil mRNA Vaccine Raw Materials Revenue (2020-2025) & (US$ Million)
Figure 56. Argentina mRNA Vaccine Raw Materials Revenue (2020-2025) & (US$ Million)
Figure 57. Middle East and Africa mRNA Vaccine Raw Materials Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Middle East and Africa Top 5 Players mRNA Vaccine Raw Materials Revenue (US$ Million) in 2024
Figure 59. South America mRNA Vaccine Raw Materials Revenue (US$ Million) by Type (2020-2031)
Figure 60. Middle East and Africa mRNA Vaccine Raw Materials Revenue (US$ Million) by Application (2020-2031)
Figure 61. GCC Countries mRNA Vaccine Raw Materials Revenue (2020-2025) & (US$ Million)
Figure 62. Israel mRNA Vaccine Raw Materials Revenue (2020-2025) & (US$ Million)
Figure 63. Egypt mRNA Vaccine Raw Materials Revenue (2020-2025) & (US$ Million)
Figure 64. South Africa mRNA Vaccine Raw Materials Revenue (2020-2025) & (US$ Million)
Figure 65. mRNA Vaccine Raw Materials Industry Chain Mapping
Figure 66. Channels of Distribution (Direct Vs Distribution)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
